. 2006 Dec 29;8(6):R73. doi: 10.1186/bcr1631

Table 2.

Multivariate analyses of ability of Shc proteins to predict failure of tamoxifen therapy

	Population cohort		Case-control cohort
Model	HR^a(95% CI)	P^b	RR^a(95% CI)	P^b
PY-Shc, p66 Shc	8.6 (2.6–30)	0.001	7.7 (1.4–44)	0.022
PY-Shc, p66 Shc
Adjusted for nodal status	8.3 (1.8–38)	0.007	12.1 (1.7–86)	0.013

^aHR (interquartile) is the RR of relapse comparing patients in the 75th percentile of PY-Shc and 25th percentile of p66 Shc to patients in the 25th percentile of PY-Shc and 75th percentile of p66 Shc. The multivariate Cox model containing PY-Shc and p66 Shc was adjusted for nodal status, AJCC (American Joint Committee on Cancer) stage (population-based cohort), tumor stage, tumor grade, progesterone receptor status, and patient age at diagnosis. ^bSignificance using Wald statistic. CI, confidence interval; HR, hazard ratio; PY-Shc, tyrosine-phosphorylated Shc; RR, relative risk.